Enhancing the efficacy of androgen signaling inhibitors in prostate cancer

增强雄激素信号抑制剂在前列腺癌中的功效

基本信息

  • 批准号:
    10294787
  • 负责人:
  • 金额:
    $ 46.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Title: Enhancing the efficacy of androgen signaling inhibitors in prostate cancer Abstract It has been documented that androgen receptor (AR) signaling remains to play a critical role in castration- resistant prostate cancer (CRPC). Indeed, Androgen Signaling Inhibitors (ASI), such as abiraterone, an inhibitor of de novo androgen synthesis pathway, and enzalutamide, a direct AR inhibitor, are major drugs used in clinic to manage CRPC now. Unfortunately, ASI-based treatment only improves the overall patient survival by several months. Therefore, understanding the underlying mechanisms of ASI resistance and development of novel avenues to increase the efficacy of ASI-based therapy are urgently needed. With the goal to identify new pathways/targets whose inhibition might overcome ASI resistance, we performed extensive bioinformatics analyses of RNA-seq data including those from paired prostate cancer (PCa) cells with different sensitivities to enzalutamide, 498 PCa tumors with different responses to hormone therapy and 52 pairs of PCa specimen (tumors vs adjacent normal). Both the -catenin- dependent canonical Wnt cascade and the -catenin-independent non-canonical Wnt signaling were identified as pathways whose elevation might contribute to acquisition of ASI resistance. The objective of the proposed research is to define the roles of Wnt signaling in acquisition of ASI resistance in CRPC and to exploit these pathways as novel therapeutic targets for CRPC patients who no longer respond to ASIs. The central hypothesis is that Wnt signaling causes constitutive activation of AR signaling, thus CRPC progression and development of ASI resistance. This hypothesis will be tested by pursuing three Specific Aims - (1) to dissect the role of-catenin signaling in enzalutamide resistance of PCa; (2) to examine how activation of the non-canonical Wnt signaling contributes to enzalutamide resistance in PCa; and (3) to test whether simultaneous inhibition of canonical and non-canonical Wnt cascades is an effective approach to treat enzalutamide-resistant PCa and to probe the significance of tumor microenvironment Wnt in the acquisition of enzalutamide resistance. These complementary aims will be accomplished using biochemical analyses of signaling intermediates and employing gain-of-function and loss-of-function strategies with inducible PCa mouse models, culture systems, human PCa xenograft, and patient-derived organoid methodologies. The rationale for the research is that it will be the first to comprenhensively probe the importance of Wnt signaling in acquisition of ASI resistance of CRPC. This contribution is significant because it will (i) define the molecular mechanism by which Wnt signaling activates AR; (ii) genetically evaluate how these pathways contribute to PCa progression and metastasis; and (iii) demonstrate Wnt cascades as critical therapeutic targets to enhance the efficacy of ASI.
标题:提高雄激素信号转导抑制剂治疗前列腺癌的疗效 摘要 已有文献证明,雄激素受体(AR)信号在去势中仍发挥关键作用。 耐药前列腺癌(CRPC)。事实上,雄激素信号抑制物(ASI),如阿比特龙, 雄激素从头合成途径的抑制剂和直接的AR抑制剂苯扎鲁胺是主要药物 现已用于临床对CRPC的管理。不幸的是,基于ASI的治疗只改善了整体 患者存活时间延长了几个月。因此,了解ASI的潜在机制 提高基于ASI的治疗效果的新途径的抗药性和开发迫在眉睫 需要的。以识别其抑制可能克服ASI抗性的新途径/靶点为目标, 我们对rna-seq数据进行了广泛的生物信息学分析,包括来自配对前列腺的数据。 对苯扎鲁胺敏感性不同的癌细胞(PCa),498个不同反应的PCa肿瘤 激素治疗组和52对PCa标本(肿瘤与癌旁正常对照)。-连环蛋白- 依赖的正则WNT级联和非依赖的非正则WNT信号是 被确定为其升高可能有助于获得ASI抵抗的途径。目标是 本研究的目的是明确Wnt信号在CRPC获得ASI抗性中的作用 并开发这些途径作为CRPC患者的新治疗靶点,这些患者对 阿希斯。中心假设是Wnt信号导致AR信号的结构性激活,从而 CRPC的进展与ASI耐药性的发展。这一假设将通过追求三个方面来检验 具体目的:(1)剖析-连环蛋白信号在前列腺癌对苯扎鲁胺耐药中的作用;(2) 研究非典型Wnt信号的激活如何促进苯扎鲁胺的耐药性 PCA;以及(3)测试同时抑制正则和非正则WNT级联是否 治疗苯扎鲁胺耐药PCa的有效途径及肿瘤意义的探讨 微环境Wnt在获得苯扎鲁胺耐药性中的作用。这些互补的目标将是 使用信号中间体的生化分析和使用功能增益和 通过可诱导的PCA小鼠模型、培养系统、人PCA异种移植、 和病人衍生的有机化合物方法学。这项研究的基本原理是,它将是第一个 综合探讨Wnt信号在CRPC获得ASI抗性中的重要性。这 贡献是重大的,因为它将(I)定义Wnt信号转导的分子机制 激活AR;(Ii)从遗传学角度评估这些通路如何促进前列腺癌的进展和转移; 以及(Iii)证明WNT级联反应是提高ASI疗效的关键治疗靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

XIAOQI LIU其他文献

XIAOQI LIU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('XIAOQI LIU', 18)}}的其他基金

Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate Cancer
靶向 Plk1/Pdcd4/mTORC2 信号传导治疗去势抵抗性前列腺癌
  • 批准号:
    10731943
  • 财政年份:
    2023
  • 资助金额:
    $ 46.73万
  • 项目类别:
Plk1 as a prognostic biomarker for prostate cancer
Plk1 作为前列腺癌的预后生物标志物
  • 批准号:
    10664904
  • 财政年份:
    2021
  • 资助金额:
    $ 46.73万
  • 项目类别:
Plk1 as a prognostic biomarker for prostate cancer
Plk1 作为前列腺癌的预后生物标志物
  • 批准号:
    10437929
  • 财政年份:
    2021
  • 资助金额:
    $ 46.73万
  • 项目类别:
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer
增强雄激素信号抑制剂在前列腺癌中的功效
  • 批准号:
    10659141
  • 财政年份:
    2021
  • 资助金额:
    $ 46.73万
  • 项目类别:
Plk1 as a prognostic biomarker for prostate cancer
Plk1 作为前列腺癌的预后生物标志物
  • 批准号:
    10306968
  • 财政年份:
    2021
  • 资助金额:
    $ 46.73万
  • 项目类别:
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer
增强雄激素信号抑制剂在前列腺癌中的功效
  • 批准号:
    10427416
  • 财政年份:
    2021
  • 资助金额:
    $ 46.73万
  • 项目类别:
Improving chemotherapy of castration-resistant prostate cancer
改善去势抵抗性前列腺癌的化疗
  • 批准号:
    9973149
  • 财政年份:
    2019
  • 资助金额:
    $ 46.73万
  • 项目类别:
Improving chemotherapy of castration-resistant prostate cancer.
改善去势抵抗性前列腺癌的化疗。
  • 批准号:
    10663219
  • 财政年份:
    2016
  • 资助金额:
    $ 46.73万
  • 项目类别:
Enhancing anti-neoplastic activity of metformin in prostate cancer
增强二甲双胍在前列腺癌中的抗肿瘤活性
  • 批准号:
    9220731
  • 财政年份:
    2016
  • 资助金额:
    $ 46.73万
  • 项目类别:
Improving chemotherapy of castration-resistant prostate cancer.
改善去势抵抗性前列腺癌的化疗。
  • 批准号:
    10316730
  • 财政年份:
    2016
  • 资助金额:
    $ 46.73万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.73万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 46.73万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 46.73万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.73万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.73万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 46.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 46.73万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 46.73万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 46.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 46.73万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了